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were signiﬁcantly associated with PFS. Post-ASCT PET(-) CR
had signiﬁcantly longer PFS than patients with PET(+) CR
(31.4  9.9 vs 18.4  3.5 months; p¼.029). In conclusion,
having an ISS-3 stage myeloma, pre and post-ASCT response
<VGPR had negative impact on PFS. Contamination of PBSC
harvests with APC was associated with shorter PFS. Our re-
sults also demonstrate the importance of achieving PET
negativity after transplantation. Thus, not only an immuno-
logical CR but also PET(-) CR should be achieved for long
term PFS.128
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Introduction: High-dose therapy with AutoHCT is a stan-
dard component of therapy for many patients with Hodgkin
(HL) and non-Hodgkin lymphoma (NHL). IPS is a known
toxicity of AutoHCT which can cause signiﬁcant morbidity
and mortality. The most common agent associated with IPS
has traditionally been high-dose BCNU (carmustine). Data on
incidence of IPS in recent era and its relation with condi-
tioning regimens are scarce.
Methods and Patients: Using the Center for International
Bone Marrow Transplant Registry (CIBMTR), we studied
4,573 patients with lymphoma who underwent AutoHCT
from 1995-2008 using the following conditioning regimens:
BEAM (n¼1730), CBVlow (n¼1249), CBVhigh (n¼604), BuCy
(n¼789), and CyTBI (n¼545). We investigated the reported
incidence of and explored clinical risk factors for its devel-
opment, including the dose of BCNU and its impact on
outcome (above vs. below 375 mg/m2 in CBV regimens). We
then analyzed the impact of IPS on outcomes including
transplant-related mortality (TRM), progression-free sur-
vival (PFS), and overall survival (OS). Use of different regi-
mens was as follows:
Results: The incidence of IPS by 1 year after AutoHCT was:
BEAM (3%), CBVlow (3%, HR 1.07 [0.72,1.60], p¼0.742), CBVhigh
(6%, HR 1.88 [1.24, 2.83], p¼0.003), BuCy (4%, HR 1.25 [0.82,1.92], p¼.30), and CyTBI (5%, HR 2.03 [1.30, 3.19], p¼.002).
Multivariate analysis showed the following risk factors for
developing IPS: 1) HL (HR 2.33, [1.68, 3.24], p < .001), 2)
female gender (HR 1.39 [1.05, 1.82], p¼.019), 3) chemo-
therapy-resistant disease at time of AutoHCT (HR 1.9 [1.29,
2.79], p¼.001), and age 55 (HR 1.54, [1.13, 2.09], p¼.006). In
the entire cohort, patients who developed IPS had a signiﬁ-
cantly higher rate of TRM (HR 4.02, [3.09, 5.24], p < .001),
shorter PFS (HR 1.82, [1.51, 2.20], p < .001), and shorter OS
(HR 2.46, [2.06, 2.94], p < .001).
Conclusion: IPS remains an important toxicity after AutoHCT
for patients with lymphoma and adversely effects overall
outcomes. Risk factors include higher doses of BCNU, TBI,
female gender, older age, chemotherapy resistant disease
and a diagnosis of HL. Investigation into strategies for the
prevention of IPS after ASCT is warranted.129
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The importance of optimal long term engraftment after
autologous stem cell transplantation is uncertain. We con-
ducted a retrospective analysis of long term engraftment in
patients who underwent autologous peripheral blood stem
cell transplant for non-Hodgkin lymphoma, Hodgkin lym-
phoma or multiple myeloma. Patients who relapsed or died
prior to assessment of long term engraftment at 1 year were
excluded. Optimal engraftment was deﬁned by NCI CTCAE
grade 1 criteria for cytopenias (ANC  1500/ml, platelets 
75000/ml, hemoglobin  10g/dL). 225 patients were iden-
tiﬁed with engraftment data at 1 year (92 NHL, 62 HL, 71
MM). Themedian follow-upwas 5.0 years for all patients (5.5
for living patients).
88% of patients achieved optimal engraftment at 1 year. The
median cell dose was 4.7 x10
ˇ
6 CD34+ cells/kg, and our
institutional minimum cell dose is 2 x10
ˇ
6 CD34+ cells/ kg.
CD34 cell dose  3 x10 ˇ6 CD34+ cells/kg and age < 60 were
predictive for optimal long term engraftment. Disease type,
gender, number of prior therapies and prior radiation ther-
apy were not predictive of achieving long term engraftment.
By landmark analysis at 1 year, optimal engraftment was not
predictive for progression free survival or overall survival in
all patients, although there was a trend for worse outcome
with poor engraftment in HL and NHL.
Incomplete long term engraftment after autologous trans-
plant is relatively rare with the most important predictors
identiﬁed as CD34 cell dose and age. For those patients who
survive one year, PFS and OS are not diminished afterward.130
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Table 1
Patient Characteristics
Day +1 Day +7
# Patients 83 56
Age 56 50.9
Sex 36 F, 47 M 24 F, 23 M
Race White:74 Black: 9 White: 49 Black:6
Hispanic:1
Wt 85.06 86.64
KPS 84.08 84.46
CMI 3.108 2.929
# of Prior Treatments 2.1 2.7
Multiple Myeloma 50 30
Lymphoma 30 22
Other* 3* 4
Patients Undergoing a
Second Transplant
4 4
*BuVP 2; VPCARB 1.# BCNUTHIO:2 BPCARB:1 TBICY:1
Table 2
Transplantation Data Following Engraftment
Day+1 Day+7 P Value
Transplanted
CD 34+ cells
5.024 4.018 .0617 (95% C.I. -2.062 to 0.04946)
Leukocyte
Reconstitution
ANC >500
9.9 11.43 <.0001 (95% C.I. 1.136 to 1.914)
Leukocyte
Reconstitution
ANC >1500
10.86 12.75 .0001 (95% C.I. 0.06929 to 2.096)
Platelet
Reconstitution
>20
19.48 20.61 .3577 (95% C.I. -1.298 to 3.569)
Platelet
Reconstitution
>50
21.12 21.84 .6821 (95% C.I. e2.749 to 4.118)
Length of Stay 18.16 18.91 .3982 (95% C.I. -1.006 to 2.514)
Table 3
Infection rates
Day +1 Day +7 P Value ( Fisher’s Exact Test)
Total Blood Stream
Infections (BSI)
23 14 .8453
Peripheral BSI 11 10
Line Associated BSI 12 6
UTI 19 7 .1827
Other 2* 2
*1 sputum with proteus mirabilis, 1 lesion with candida glabrata, 1 sputum
with Candida, 1 throat culture with beta hemolytic strep
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Purpose: Prior studies have suggested associations with
vitamin D concentrations, increased survival and prognosis
in patients with lymphoma and multiple myeloma (MM);
however little is known about patients undergoing autolo-
gous hematopoietic stem cell transplant (AHSCT). We, thus,
investigated pre-AHSCT 25-hydroxyvitamin D [25(OH)D]
concentrations and transplant related parameters to deter-
mine incidence of vitamin D insufﬁciency and overall sur-
vival in subjects diagnosed with MM and lymphoma.
Methods: An IRB approved waiver of consent retrospective
analysis was performed at Seattle Cancer Care Alliance
(SCCA) in Seattle, Washington. Retrospective data, from May
2009 and May 2010, were collected from the electronic
medical records of AHSCT adults (n¼132) diagnosed with
MM (n¼70) and lymphoma (n¼62). Variables collected
included mean pre-AHSCT total 25(OH)D concentrations,
age, gender, race, ethnicity, geographic residence, body mass
index (BMI), vitamin D-containing supplement use, date of
death, and date of last contact.
Results: The majority of both male and female subjects were
>50 years old, white and non-Hispanic/Latino, overweight or
obese, living above the 37th parallel, and reported the use of a
vitamin D-containing supplement. Age was positively asso-
ciated to disease (p¼ .002, t-test), whereas other parameters
were not. Mean pre-transplant 25(OH)D concentrations of
29.0  11.0ng/mL (p ¼ <.001, t-test) suggested a signiﬁcant
incidence of vitamin D insufﬁciency in the sample. The re-
ported use of a vitamin D-containing supplement was the
only parameter signiﬁcantly associated with 25(OH)D con-
centrations (p ¼ .014). Ultimately, pre-transplant vitamin D
status (insufﬁcient vs sufﬁcient) had no signiﬁcant impact on
overall survival in subject’s post-AHSCT [HR ¼ 0.99 (95% CI
0.45-2.20) Log-rank p¼ .997].
Conclusion: The majority of lymphoma and MM patients
have insufﬁcient pre-AHSCT 25(OH)D concentrations. In
contrast to prior studies, no association of 25(OH)D and
survival was observed. These ﬁndings support a rationale to
continue this investigation in a larger prospective sample.
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Background: Giving Filgrastim (G-CSF) following high dose
chemotherapy and autologous stem cell reinfusion (HSCT) is
routinely used to shorten duration of neutropenia and
decrease risk of infection. The optimal post-transplant day of
initiation of G-CSF is not standardized. We recently studied a
change from initiation of G-CSF from day +1 to day +7 in light
of recent data showing equivocal results.
Methods: Beginning November 1st, 2012 a control group
consisting of 83 patients with multiple myeloma or lym-
phoma undergoing autologous HSCT received G-CSF subcu-
taneously daily from Day+1 until absolute neutrophil count
(ANC) of 1500 for two consecutive days. Beginning February
1st, 2013 we evaluated 56 patients who received G-CSF
starting day +7 and compared time to ANC engraftment be-
tween the groups. Both groups received G-CSF to the same
ANC endpoint. Patients were matched for diagnosis, comor-
bidity index, number of prior therapies, and performancestatus. Additional endpoints included incidence of infection,
transfusion support, and length of stay.
Results: 83 patients in the control group received G-CSF
beginning day +1, and 56 study group patients received G-
CSF beginning day +7. There was a signiﬁcant difference in
ANC recovery both to >500 and >1500 between the groups.
On average, patients who received G-CSF starting Day +7
required 1.53 more days for ANC recovery >500 and 1.89
more days for ANC recovery >1500. However, there was no
statistical difference in platelet reconstitution or length of
stay.
Conclusion: Day +1 administration of G-CSF was associated
with earlier neutrophil recovery but there was no improve-
ment in incidence of infection or length of stay when
compared to administration beginning day +7.
